Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Talion Authorized Generics to Launch on March 1
January 11, 2018
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Lenvima-Keytruda Combo Earns FDA’s Breakthrough Designation for RCC
January 10, 2018
- GSK Canada Head Tapped for Japan President
January 10, 2018
- ALL Med Blinatumomab Filed in Japan: Amgen Astellas
January 10, 2018
- Takeda Snaps Up Cell Therapy Partner TiGenix in GI, Partners with Denali in CNS
January 9, 2018
- Chugai Executes Asset Transfer for 13 Off-Patent Brands
January 9, 2018
- Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions
January 1, 2018
- Nissui Pharma to Invest in Keio Univ. Spinoff Specializing in Saliva-Based Tests
December 28, 2017
- China FDA Puts Lenvima on Priority Review for HCC
December 28, 2017
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Generic Use Rate at 68.8% in July-September: JGA
December 27, 2017
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Otsuka Group to Invest 1 Billion Yen in Kyoto Startup, Aims to Commercialize iPS Cell-Derived Platelets
December 26, 2017
- Maruho Grabs Global Rights to RaQualia’s Sodium Channel Blocker
December 26, 2017
- MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?
December 26, 2017
- 86 Apply for Voluntary Redundancy for Manufacturing Jobs: Sumitomo Dainippon
December 26, 2017
- TB Vaccine Joint Venture to Be Dissolved: Sumitomo Dainippon, Japan BCG, INCJ
December 26, 2017
- Kyowa Kirin Taps Miyamoto as President and COO
December 25, 2017
- Opdivo Filed for Dosage Change, Label Expansion in Japan
December 25, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…